As Vitality becomes the first UK insurance provider to offer discounted weight-loss jab treatment, Yahoo UK spoke to them to ...

Ozempic and other glucagon-like peptide-1 (GLP-1) agonists are a transformative new class of medicines for the treatment of ...

A new study adds to a growing body of evidence that semaglutide has benefits other than weight loss or controlling diabetes.

Eli Lilly has launched new single-dose 2.5mg and 5.0mg vials of its obesity ... are a lower-cost alternative to the current injector pen formulation of Zepbound and are easier to produce.

Here is more information on Wegovy, how to decide if it’s right for you, and what you need to know about the Wegovy ...

In obesity, it will compete with Novo Nordisk’s GLP-1 agonist Wegovy (semaglutide), which ... is currently available in the original singe-dose pen-injector format. Mounjaro has already been ...

A small study confirms observations what users have observed: the medications reduce their cravings for alcohol.

The case for GLP-1 drugs like Ozempic possibly causing blindness is building. A new paper out this week describes several ...

For years, people taking Ozempic or other drugs in the same class for diabetes and weight loss have noticed the medicines don ...

An ad airing Super Bowl Sunday features “America’s deadliest epidemic,” obesity, and what can be done about it with the use of “affordable” compounded weight loss drugs.

The drug semaglutide has been linked to a lower risk of alcoholism before, but now we have strong evidence that it really ...

COPENHAGEN--Novo Nordisk will launch its hugely popular anti-obesity drug Wegovy in Japan on Feb. 22 ... for a 0.25-milligram starter dose and 42,960 yen for a 2.4 mg dose, Novo said.